Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Surfactant associated 1, pseudogene (SFTA1P) is a **long non-coding RNA (lncRNA)** of pseudogene origin, highly expressed in lung tissue and implicated in diverse cancers. It shows **tumor suppressor activity in lung squamous cell carcinoma, non-small cell lung cancer, and gastric cancer**, with downregulation associated with increased proliferation, migration, invasion, and poor prognosis[1][2][3][5][6]. Mechanistically, SFTA1P regulates various cancer signaling pathways, acting as a feedback modulator of Hippo-YAP/TAZ, and influencing PI3K-AKT and cell cycle checkpoints[2][4]. SFTA1P can enhance cancer cell apoptosis and sensitivity to cisplatin via the hnRNP-U–GADD45A axis[3]. In cervical cancer, however, SFTA1P functions as an oncogene by promoting malignant phenotypes through interaction with PTBP1 and destabilization of TPM4 mRNA[7]. Its consistently cancer-associated features suggest utility as a **biomarker for prognosis and therapy response**, but not as a classic druggable protein target.
For cisplatin: SFTA1P upregulation increases apoptosis and chemosensitivity in lung squamous cell carcinoma through hnRNP-U–GADD45A pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Surfactant associated 1, pseudogene, long non-coding RNA (SFTA1P).